Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prices Could Be Slashed Under U.K.’s New Drug-Pricing Scheme

This article was originally published in The Pink Sheet Daily

Executive Summary

Prices may decrease, but at least wider societal benefits are to be included in NICE’s assessment in the U.K.’s new value-based pricing (VBP) scheme for new pharmaceuticals, a change long demanded by critics of the health technology assessment body.

Advertisement

Related Content

Pharma Hopes EU Commission Policy Report Will Lead To Real Dialogue
Pharma Hopes EU Commission Policy Report Will Lead To Real Dialogue
Pharma Hopes EU Commission Policy Report Will Lead To Real Dialogue
U.K. Deal Reached For 5-Year Price Cap On State’s Branded Drug Regulation
European Notebook: Renewed Calls For German Pricing Law Changes, Spain Gauges The Value Of Innovation
Curative Regenerative Drugs Need NICE Rethink, Key U.K. Committee Says
UK Value-Based Pricing Proposals Aim To Increase Access, Broaden Assessment of Drug Benefits

Topics

Advertisement
UsernamePublicRestriction

Register

PS075862

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel